BioSpace News Archive

Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202 million with an undisclosed, large commercial-stage biopharmaceutical company under which such company will develop and commercialize antibody-based products targeting a tumor-associated carbohydrate antigen (TACA) identified by Siamab’s proprietary TACA discovery platform.

IDTechEx, a market intelligence and events company focused on emerging technologies, reports that the market for 3D printed medical devices and pharmaceuticals will be worth $6.1 billion by the year 2029.

The Nature’s Bounty Co., a global leader in health and wellness, today announced that Faissal Tahiri has joined the company as President, International, reporting to President and CEO Paul Sturman.

OKYO Pharma Limited (LSE: OKYO), a biotechnology company developing targeted drugs for inflammatory dry eye diseases and chronic pain, is pleased to announce a collaborative agreement with Pedram Hamrah, MD, Ophthalmology Scientist and Cornea Specialist at Tufts Medical Center, and Professor of Ophthalmology at Tufts University School of Medicine, Boston, MA, to evaluate proprietary lead compounds, targeting G-protein coupled receptors (“GPCRs”), as non-opioid analgesics.

Company’s innovative program recognized for encouraging people to engage in healthy habits

Syzygy Plasmonics, a technology company developing the world’s highest performance photocatalyst, today announced it has raised $5.8 million in Series A funding.

MedChain, Inc., an early stage company building globally compliant healthcare blockchain and decentralized applications (dApps) for electronic medical records (EMRs), announces the filing of its Provisional Patent Application related to methods of securely storing patient medical records utilizing Blockchain technology.

The Barbara Ann Karmanos Cancer Institute is the first cancer center in Michigan to acquire and treat patients with the new Leksell Gamma Knife® Icon™, the most precise stereotactic radiosurgery system (SRS) currently available to patients.

PharmaMar (MSE: PHM) today announced that the FDA (Food and Drug Administration) agreed with PharmaMar’s proposal to file for accelerated approval its New Drug Application (NDA) for lurbinectedin monotherapy for the treatment of second-line SCLC.

Botanacor Laboratories, the widely recognized leader in accredited testing of hemp biomass and hemp-derived CBD products, is responding to rising demand by offering industrial hemp and CBD testing not just in Colorado, but throughout all of North America.